Tempest Therapeutics, Inc. (NASDAQ:TPST) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) with series C and series D warrants Announced: about US$2.5M · US$0.805 a share · Warrants at US$0.805 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and other general corporate purposes | Sep 11, 2026 |
| Strategic investment of investment commitment Update: strategic investment Buyers: Factor Bioscience Inc. (investment commitment / financing support) Use of proceeds: Together with existing cash, expected to provide a runway to mid-2027 and potentially through key data milestones | Feb 4, 2026 |
| Registered direct offering of shares of common stock (or common stock equivalents) with concurrent private placement of short-term unregistered warran Closed: US$4.25M raised · US$3.625 a share · Warrants at US$3.5 for 18 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Primarily working capital and general corporate purposes | Nov 26, 2025 |
| Registered direct offering of shares of common stock (or common stock equivalents) Announced: about US$4.6M · US$6.25 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: single institutional investor (739,000 shares of common stock (or common stock equivalents)) Use of proceeds: Supporting the previously announced strategic alternative process, working capital and general corporate purposes | Jun 11, 2025 |